Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rogers Kerry A, Yan Pearlly, Flinn Ian W, Stephens Deborah M, Kipps Thomas J, Larson Sarah M, Martz Laura, Chen Xi, Wang Huabao, Hopping Ethan, Bundschuh Ralf, Turkoglu Altan, Lozanski Gerard, McGarry Carolyn, Acosta Alexandra, Sechaud Romain, Baldoni Daniela, Chaudhury Anwesha, Whalen Jeanne, Hassounah Nadia B, Orwitz Nina, Otero Javier, Woo Janghee, Byrd John C
Аннотация
PURPOSE: This phase Ib dose-escalation/expansion trial (NCT03400176) enrolled patients with CLL who did not achieve a complete response (CR) with ibrutinib or had developed resistance mutations. Ianalumab (VAY736), an anti-B cell-activating factor receptor monoclonal antibody, combined with ibrutinib significantly improved survival and reduced tumor burden in preclinical chronic lymphocytic leukemia (CLL) models.
PATIENTS AND METHODS: Patients received intravenous ianalumab (escalation: 0.3-9.0 mg/kg; expansion: 3.0 mg/kg) once every 2 weeks and continued ibrutinib (420 mg) once daily for up to eight cycles of 28 days. The study aimed to evaluate the safety, tolerability, recommended dose, and antitumor activity of this combination.
RESULTS: Thirty-nine patients were treated (escalation: n = 15; expansion: n = 24). No dose-limiting toxicities were observed. Of the 39 patients, 38.5% were in CR or CR with incomplete marrow recovery at cycle 9 (C9). At C9 day 1, 17 patients (43.6%) achieved undetectable measurable residual disease in blood or bone marrow. Grade ≥3 adverse events occurred in 16 patients (41.0%), which were treatment-related in nine (23.1%). No on-treatment deaths were reported; one patient died because of COVID-19 during the posttreatment period. Seventeen patients (43.6%) discontinued ibrutinib at or after C9 day 1 and remained off therapy for 12.1 to 24.5 months. Preliminary RNA sequencing and flow cytometry data support both NK- and T-cell activation with ianalumab.
CONCLUSIONS: The combination was well tolerated, with 43.6% of patients discontinuing ibrutinib therapy. Biomarker data suggest that ianalumab increased NK- and T-cell activation. These data support further evaluations of ianalumab in combination with Bruton tyrosine kinase inhibitors for patients with CLL.
PATIENTS AND METHODS: Patients received intravenous ianalumab (escalation: 0.3-9.0 mg/kg; expansion: 3.0 mg/kg) once every 2 weeks and continued ibrutinib (420 mg) once daily for up to eight cycles of 28 days. The study aimed to evaluate the safety, tolerability, recommended dose, and antitumor activity of this combination.
RESULTS: Thirty-nine patients were treated (escalation: n = 15; expansion: n = 24). No dose-limiting toxicities were observed. Of the 39 patients, 38.5% were in CR or CR with incomplete marrow recovery at cycle 9 (C9). At C9 day 1, 17 patients (43.6%) achieved undetectable measurable residual disease in blood or bone marrow. Grade ≥3 adverse events occurred in 16 patients (41.0%), which were treatment-related in nine (23.1%). No on-treatment deaths were reported; one patient died because of COVID-19 during the posttreatment period. Seventeen patients (43.6%) discontinued ibrutinib at or after C9 day 1 and remained off therapy for 12.1 to 24.5 months. Preliminary RNA sequencing and flow cytometry data support both NK- and T-cell activation with ianalumab.
CONCLUSIONS: The combination was well tolerated, with 43.6% of patients discontinuing ibrutinib therapy. Biomarker data suggest that ianalumab increased NK- and T-cell activation. These data support further evaluations of ianalumab in combination with Bruton tyrosine kinase inhibitors for patients with CLL.